Characteristics | Patients ( |
---|---|
Age: | |
≤62 years | 148 (49.3) |
≥62 years | 152 (50.7) |
Gender: | |
males | 238 (50.7) |
females | 62 (20.7) |
Smoking habit: | |
smoker | 233 (74.3) |
never smoked | 77 (25.7) |
Histological type: | |
adenocarcinoma | 228 (76.0) |
squamous | 62 (20.7) |
other | 10 (3.3) |
Stage: | |
early (I; II; IIIA) | 70 (23.3) |
advanced (IIIB; IV) | 230 (76.7) |
Mutation | Exon | Nucleotide Number | Amino Acid Changes | Mutation |
---|---|---|---|---|
Point mutation | 18 | 2155 (G>T) | G719C | 1 (0.8%) |
Point mutation | 18 | 2134 (G>A) | G719S | 3 (2.5%) |
Point mutation | 18 | 2155 (G>A) | G719A | 9 (7.6%) |
Deletion | 19 | 235-2249del (GGA ATT AAG AGA AGC) | delE746-A750 | 39 (33.4%) |
Del/Ins | 19 | 2235-2252del (GGA ATT AAG AGA AGC insCA) | L747-6751insP | 10 (8.5%) |
Del/Ins | 19 | 2235-2252del (GGA ATT AAG AGA AGC insAAT) | delE746-T751insI | 5 (4.2%) |
Del/Ins | 19 | 2235-2258del (GGA ATT AAG AGA AGC insAAT CCA) | delE746-A750insIP | 1 (0.8%) |
Del/Ins | 19 | 2235-2249del (GGA ATT AAG AGA AGC insAGA) | delL747-P753insS | 3 (2.5%) |
Del/Ins | 19 | 2235-2258del (GGA ATT AAG AGA AGC insAAT) | delE746-A750insI | 3 (2.5%) |
Del/Ins | 19 | 2235-2258del (GGA ATT AAG AGA AGC insCCA) | delA746-A750insP | 1 (0.8%) |
Del/Ins | 19 | 2235-2258del (GGA AAT AAG AGA AGC insCAA) | delL747-T751insQ | 1 (0.8%) |
Point mutation | 20 | 2369 (C>T) | T790M | 3 (2.5%) |
Point mutation | 21 | 2573 (T>G) | L858R | 10 (8.5%) |
Point mutation | 21 | 2582 (T>A) | L861Q | 29 (24.6%) |
Mutation Types | Codon | Nucleotide Number | Amino Acid Changes | Mutations |
---|---|---|---|---|
Point mutation | 12 | 34 (G>A) | G12S | 10 (12.7%) |
Point mutation | 12 | 34 (G>T) | G12C | 8 (10.1%) |
Point mutation | 12 | 35 (G>A) | G12D | 6 (6.7%) |
Point mutation | 12 | 35 (G>T) | G12V | 20 (25.2%) |
Point mutation | 12 | 35 (G>A) | G12A | 1 (1.3%) |
Point mutation | 13 | 37 (G>A) | G13D | 1 (1.3%) |
Point mutation | 61 | 182 (A>G) | Q61R | 18 (22.8%) |
Point mutation | 61 | 183 (A>C) | Q61H | 15 (19.0%) |
Characteristics | Patients | EGFR Mutations (32.33%) | KRAS Mutations (25.0%) | EGFR and KRAS Mutations (6.6%) | |||
---|---|---|---|---|---|---|---|
( | [+] ( | [–] ( | [+] ( | [–] ( | [+] ( | [–] ( | |
Age: | |||||||
≤62 years | 148 | 50 (32.9%) | 102 (67.1%) | 32 (21.1%) | 120 (78.9%) | 7 (4.6%) | 145 (95.4%) |
≥62 years | 152 | 47 (31.8%) | 101 (68.2%) | 43 (29.1%) | 105 (70.9%) | 13 (8.8%) | 135 (91.2%) |
Gender: | |||||||
males | 238 | 67 (28.2%) | 171 (71.8%) | 63 (26.5%) | 174 (73.5%) | 16 (6.7%) | 222 (93.3%) |
females | 62 | 30 (48.3%)a | 32 (51.7%) | 12 (19.4%) | 50 (80.6%) | 4 (6.5%) | 58 (93.5%) |
Smoking habit: | |||||||
smoker | 233 | 59 (26.5%) | 164 (73.5%) | 58 (26.0%) | 165 (74.0%) | 11 (4.9%) | 212 (88.4%) |
never smoked | 77 | 38 (49.4%)a | 39 (50.6%) | 17 (22.0%) | 60 (78.0%) | 9 (11.6) | 68 (88.4%) |
Histological type: | |||||||
adenocarcinoma | 228 | 77 (33.7%)a | 151 (66.3%) | 55 (24.1%) | 173 (75.9%) | 16 (7.0%) | 212 (93.0%) |
squamous | 62 | 13 (21.0%) | 49 (79.0%) | 18 (29.0%) | 44 (71.0%) | 2 (3.2%) | 60 (96.8%) |
other | 10 | 7 (70.0%) | 3 (30.0%) | 2 (20.0%) | 8 (80.0%) | 2 (20.0%) | 8 (80.0%) |
Stage: | |||||||
early (I; II; IIIA) | 70 | 18 (25.7%) | 52 (74.3%) | 16 (22.8%) | 54 (77.2%) | 2 (2.8%) | 68 (97.2%) |
advanced (IIIB; IV) | 230 | 79 (34.3%) | 151 (65.7%) | 59 (25.6%) | 171 (74.4%) | 18 (7.8%) | 212 (92.2%) |